

Hist - 165' con

wt - 66.8 kg.

m3 - 9168589520

D03 - 25 ~~30~~ Feb 2005

(G1 Primi) Triple test - Low Risk

Name: Vandana Yadav Checkup Schedule (Morning) - Tues, Thu, Sat 9:00 AM to 11:30 AM

GRAVIDA G1 LMP 01/3/25 EDD 8/12/25 DRUG ALLERGY NID

INVESTIGATION DETAILS		URINE	
HB <u>11.3 gm</u>	VDRL (W) <u>Negative</u>	R - Albumin <u><</u>	M - Sugar <u><</u>
BLOOD SUGAR <u>7.6 mg/dl</u>	HIV <u>Negative</u>	SGPT <u>16.5</u>	SGOT <u>17.4</u>
BLOOD GROUP <u>B+</u>	HbSag <u>Negative</u>	S-CREAT <u>0.56 mg/dl</u>	FT4 <u>0.53 mg/dl</u>
TSH <u>1.06 uIU/ml</u>	HCV <u>Negative</u>	OTHERS	
	SICKLING	BT <u>-3 min 30 sec</u>	
		CT <u>4 min 15 sec</u>	
		PT	

PAST HISTORY	FAMILY HISTORY	INJ. T.T.	PARA.	USG	(I)	(II)
Operation <u>NID</u>	HTN <u>No</u>	1 <u>3/06/2025</u>	1	GA <u>Reduputal</u>		
Jaundice	DM	2 <u>3/7/25</u>	2	LIQ		
Blood Transfusion	Cong. ab	3	3	ANOMALY		
	Blood Disorder			PLACENTA		

Date	WT (Kg)	B P	Pulse	Edema	Gestational Period (Months)	Fundal (Ht) Weeks	Presentation	FHS	Remarks
2/5/25	64 kg	100/70		Hb-11.3 gm	2M				
22/6/25	65 kg	100/70			3M	when 31/6/25			Good 1/12/25
27/7/25	66 kg	100/60			4M	at part part			
19/7/25	65 kg	100/70		Hb-11.3 gm	extrem	16 cm			
4/8/25	66 kg	110/70			5M	25 cm			Good 1/12/25
1/9/25	67 kg	120/70			6M	22 cm			
18/9/25	68 kg	110/70		Hb-10.6 gm	6M	25 cm			
3/10/25	68 kg	130/80			7M	25 cm			Good 1/12/25



REDMI 9 POWER

Lat

Cap may nareb 812 dt and 1m - 20

Tom 2yred AT 103 m-ders

Tom Bio D3 AT 103 m-ders

Tom mainlone 1308 1410 - 30

Arginova Sachet BNPCL 1st - 22

Therapies like ✓ Desbelle

Cp Gen D3 name lobby 24/10

Program for n.c.

Cap Nava msk BNPCL 1st

Cap Siment / Febmax pho 1st - 5

Patent Name:
Prescribed By:
Sector:
Phone:
Address:

VANDANA KUMARI
Dr. Pratibha Archana
Das
N2517011877
BALGI

Age/Gender:
Doctor's Designation:
Unique ID:

20 Year / F
Obstetrics and
Gynaecology
517013510

Prescription Date:

03-10-2026 05:53:37

Korba Super Thermal Power Proj

SR NO

DESCRIPTION

CHARGES

1

OTHERS-First Consultation

100

Total Amount : ₹ 100/- (Rupees, One Hundred Only)

Valid for single consultation only.

Signature

Dr. 6/12/26

BP-130/80mmHg

WT-68kg

use on 3/10/25 - Start 29-30 wks (+1wk).

Two loops of cord - cut on the Nipping Mechanism.

Plac. mid segment - Ant - towards left -

ft 1396t 57.

ROT 12.8

Doppler study UA - Normal.

UA - Normal.

Fm - 1 of the 2 large

C.D.R. > 1 of the 2 large

D.V. flow is normal.

Had 30wks mtd

Old cold fever

170

REDMI 9 POWER



REDMI 9 POWER

GB DIAGNOSTICS

◆ SPIRAL CT SCAN ◆ DIGITAL X-RAY ◆ OPG ◆ 4D COLOR DOPPLER SONOGRAPHY ◆ EEG

Dr. Harpal Singh

M.B.B.S., D.M.R.D. (Mumbai)
Reg. No.: C.G.M.C. 1195/07
Sunday Closed

C1-C2/19, Opposite Nagar Nigam Zone Office (Pani Tanki), Near Niharika Cinema, KORBA (C.G.)

Consultant Radiologist, Sonologist
Ex. Registrar : Nair & Nanawati Hospital, Mumbai
Ph. : 07759-227700, M : 9893254400
--Reporting Time : 10 AM to 6 PM--

Name : VANDANA KUMARI Date : 03-10-2025
Ref. By Dr. : PRATIBHA A. DAS, MS [NTPC] Age/Sex : 20 / F

OBSTETRICS SONOGRAPHY (WITH COLOR DOPPLER)

L.M.P: 01/03/2025 GA: 30 WKS 06 DYS EDD: 06/12/2025

OBSERVATIONS:

There is a single, live, normal intrauterine gestation.

Foetal Movements : (++) Visualised normal
Foetal Cardiac Pulsation's : (++) Visualised normal. HR: 177 B/min.
Presentation : Vertex
Lie : Longitudinal.
Attitude : Flexion
Foetal Spine : Anterior & Right of Maternal spine .

FOETAL PARAMETERS:

B.P.D. : 75.4 mm. compatible with 30 wks. 2 dys.
Femur Length : 58.3 mm. compatible with 30 wks. 3 dys.
Head Circumference : 277 mm. compatible with 30 wks. 3 dys.
Abdominal Circumference : 241 mm. compatible with 28 wks. 3 dys.
ESTIMATED FOETAL WEIGHT : >> 1396 ± 5% << gms. (By two formulas).
PLACENTA : >> It is in mid segment located Anteriorly, TOWARDS LT & shows grade II Maturity .
AMNIOTIC FLUID : Adequate for Gestational age (AFI 12.8 PRESENTLY)
CERVIX : Normal (3.0 CM PRESENTLY).

GROSS FOETAL ANOMALIES:

GROSSLY APPEARS NORMAL .
ALL FOETAL ANOMALIES CAN NOT BE RULED OUT CONFIDENTLY PRESENTLY AT THIS GESTATION AGE DUE TO OVER CROWDING OF FOETAL PARTS .

... PLEASE CORRELATE WITH ANAMOLY SCAN IF DONE (18 - 22 WKS)

OBSTETRIC DOPPLER STUDY

(A) UTERO-PLACENTAL AXIS:


UTERINE ARTERY DOPPLER : THE MEAN UTERINE ARTERY PI >> WNL

(RT UT ARTERY PI IS > WNL , NOTCH > ABSENT & LT UT ARTERY PI IS > WNL , NOTCH > ABSENT)

Date of report: 26/06/2025
Prisca 5.0.2.37

DR.
PRATHIBHA A DAS

Patient data			Ultrasound data		
Name		MRS VANDANA KUMARI	Gestational age		11 + 5
D.O.B.		25/02/2005	Scan date		03/06/2025
Age at delivery		20.8	Method		CRL Robinson
Correction factors					
Fetuses	1	IVF	no	Previous trisomy 21	no
Weight in kg	64	diabetes	no	pregnancies	
Smoker	no	Origin	Asian		
Risks at term					
Age risk at term		1:1522	Trisomy 21		1:769
Overall population risk		1:600	Trisomy 18		<1:10000
Neural tube defects,risk		1:9390			
Pregnancy data			Parameter Value Corr. MoM		
Sample Date		23/06/2025	AFP	18.5 ng/ml	0.64
Gestational age at sample date		14 + 4	HCG	53346 mIU/ml	1.39
			uE3	0.2 ng/ml	0.68
determination method		CRL Robinson			



Trisomy 21

The calculated risk for Trisomy 21 is below the cut off which represents a low risk. After the result of the Trisomy 21 test it is expected that among 769 women with the same data, there is one woman with a trisomy 21 pregnancy and 768 women with not affected pregnancies. The calculated risk by PRISCA depends on the accuracy of the information provided by the referring physician. Please note that risk calculations are statistical approaches and have no diagnostic value!

Trisomy 18

The calculated risk for trisomy 18 is < 1:10000, which indicates a low risk.

Neural tube defects risk

The corrected MoM AFP (0.64) is located in the low risk area for neural tube defects.

☒ below cut off

☐ Below Cut Off, but above Age Risk

☐ above cut off



LABORATORY REPORT

NAME	: MRS VANDANA KUMARI	REFERRED BY	: DR.PRATIBHA ARCHANA DAS	VISIT NO	: VAMP25225877
AGE	: 20Y 3M 30D	ADVANCE DIAGNOSTIC CENTER		COLLECTED ON	: 25-06-2025 12:00
GENDER	: Female	LAB MR#	: AAMP01145806	RECEIVED ON	: 26-06-2025 14:38
OP / IP / DG #				APPROVED ON	: 26-06-2025 17:26
				REPORT STATUS	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

- In case, if the provided DOB/LMP date/gestational age or other risk factors etc. needs any correction, the risk analysis will be recalculated according to the corrected parameters to avoid technical errors, if any.

SOFTWARE GENERATED GRAPHICAL REPORT ATTACHED OVERLEAF.

Sanjeeta

Dr. Sanjeeta
Consultant- Biochemist

Disclaimer:

- All results released pertain to the specimen as received by the lab for testing and under the assumption that the patient indicated or identified on the bill/test requisition form is the owner of the specimen.
- Clinical details and consent forms, especially in Genetic testing, histopathology, as well as wherever applicable, are mandatory to be accompanied with the test requisition form. The non-availability of such information may lead to delay in reporting as well as misinterpretation of test results. The lab will not be responsible for any such delays or misinterpretations thereof.
- Test results are dependent on the quality of the sample received by the lab. In case the samples are preprocessed elsewhere (e.g., paraffin blocks), results may be compromised.
- Tests are performed as per the schedule given in the test listing and in any unforeseen circumstances, report delivery may be affected.
- Test results may show inter-laboratory as well as intra-laboratory variations as per the acceptable norms.
- Genetic reports as well as reports of other tests should be correlated with clinical details and other available test reports by a qualified medical practitioner. Genetic counselling is advised in genetic test reports by a qualified genetic counsellor, medical practitioner or both.
- Samples will be discarded post processing after a specified period as per the laboratory's retention policy. Kindly get in touch with the lab for more information.
- In accidental damage, loss, or destruction of the specimen is not attributable to any direct or negligent act or omission on the part of Ampath Labs or its employees, Ampath shall in no event be liable. Ampath lab's liability for a lack of services, or other mistakes and omissions, shall be restricted to the amount of the patient's payment for the pertinent laboratory services.





LABORATORY REPORT

NAME : MRS VANDANA KUMARI REFERRED BY : DR. PRATIBHA ARCHANA DAS VISIT NO : VAMP25225877
AGE : 20Y 3M 30D ADVANCE DIAGNOSTIC CENTER COLLECTED ON : 25-06-2025 12:00
GENDER : Female LAB MR# : AAMP01145806 RECEIVED ON : 26-06-2025 14:38
OP IP/DG# : APPROVED ON : 26-06-2025 17:26
REPORT STATUS : Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

BIOCHEMISTRY

Maternal Screening (Second Trimester) - Triple Markers (Serum.)

Alpha Feto Protein - AFP (Maternal Screening)	18.50		ng/mL
hCG - Maternal Screening	53,346.00		mIU/mL
Estriol Unconjugated - uE3 - Maternal Screening	0.20		ng/mL

Interpretation

The trisomy risk was calculated based on ultrasound gestational age, Triple marker results, patient demographics and other risk factors like history of IDD etc.

Neural Tube Defects (NTD): The calculated MoM of AFP (0.64) found below the established normal cutoff of 2.5 MoM, indicates low risk for fetal NTDs at delivery date.

Trisomy 21 (Down syndrome) & Trisomy 18 (Edwards' and Patau's syndrome) risk: The calculated risks for trisomy 21 (1:769) and trisomy 18 (1:10000) were found in the low risk category, according to the established normal cutoff (Refer Down's syndrome screening report). Please correlate clinically.

Triple Marker screening performance (for information)

Fetal abnormalities	Risk cut-off	Detection Rate (%)	FPR (%)
Neural tube defects (NTDs)	AFP MoMs ≤ 2.5	Upto 70-75%	2-4%
Trisomy 21 (Down Syndrome)	1:250	Upto 69%	<5%
Trisomy 18 (Edward & Patau's syndrome)	1:100	Upto 69%	<5%

FPR: false positive Rate; MoMs: Multiples of Medians

Remarks

The Triple marker is an effective & noninvasive blood test, performed in 2nd trimester to identify the risk of pregnant women for Down syndrome (Trisomy 21), Edward syndrome and Patau's syndrome (trisomy 18) & oral Neural Tube Defects (ONTDs). This screening test measures the levels of three substances, AFP, Beta hCG and uE3 in the maternal blood. Ideally all pregnant women should be screened for prenatal disorders irrespective of maternal age.

- Triple marker risk calculation is generated by using : Prisca 5.0.2.37 software based on triple marker results, demographics like gestational age or LMP date/ultrasound report, race and other risk factors like Insulin dependent diabetes (IDD), smoking habits (if any) etc. Patient specific risks are generated in the form of analytical MoM (Multiples of Median) values and risk cutoff percentages and it represent the likelihood ratios for each parameter falling into an affected or unaffected risk for trisomy 21 & 18.
- Prenatal screen is not a diagnostic test but rather a tool for risk assessment. A negative test does not necessarily rule out the absence of fetal defects and a positive test is not diagnostic but suggests need for further diagnosis. As the screening test does not confirm trisomy, a high risk report should be followed by Amniocentesis for confirmation.

Generated On 30-Jun-2025 12:26:56

This is an electronically authenticated laboratory report.

Page 1 of 2


Sn No: 14595052





LABORATORY REPORT

NAME : MRS VANDANA KUMARI	REFERRED BY : DR. PRATHIBHA ARCHANA	VISIT NO : VAMP25289472
AGE : 20Y 5M 12D	ADVANCE DIAGNOSTIC CENTER	COLLECTED ON : 04-08-2025 12:00
GENDER : Female	LAB MR# : AAMP01198360	RECEIVED ON : 08-08-2025 14:03
OP / IP / DG # :		APPROVED ON : 09-08-2025 16:48
		REPORT STATUS : Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

BIOCHEMISTRY

Maternal Screening (Second Trimester) - Quadruple Markers (Serum.)

Alpha Feto Protein - AFP (Maternal Screening) CLIA	50.20	ng/mL
hCG - Maternal Screening CLIA	27,396.00	mIU/mL
Estriol Unconjugated - uE3 - Maternal Screening CLIA	1.00	ng/mL
Inhibin A - Maternal Screen (CLIA)	371.50	pg/mL

Interpretation

The trisomy risk was calculated based on ultrasound gestational age, Quadruple marker results, patient demographics and other risk factors etc.

Neural Tube Defects (NTD): The calculated MoM of AFP (0.60), found below the established normal cutoff of 2.5 MoM, indicates low risk for fetal ONTDs at delivery date.

Trisomy 21 (Down syndrome) & Trisomy 18 (Edwards' and Patau's syndrome) risk: The calculated risks for trisomy 21 (1:83) found to be in high risk category and trisomy 18 (<1:10000) found in the low risk category, according to the established normal cutoff ratio of 1:250 (Refer Down's syndrome screening report). Please correlate clinically.

Quadruple Marker screening performance (for information)

Fetal abnormalities	Risk cut-off	Detection Rate (%)	FPR (%)
Neural tube defects (NTDs)	AFP MoMs ≤ 2.5	Up to 81% (with quadruple markers)	<3-5%
Trisomy 21 (Down Syndrome)	1:250	or	
Trisomy 18 (Edward & Patau's syndrome)	1:100	Up to 90% (with Quadruple markers & ultrasonography)	

Note: FPR: false positive Rate; MoMs: Multiples of Medians

Remarks

- The Quadruple marker is an effective & noninvasive maternal blood test, performed in 2nd trimester to identify the risk of pregnant women for Down syndrome (Trisomy 21), Edward & Patau's syndrome (trisomy 18) & Neural Tube Defects (ONTDs). This screening test measures the levels of four substances, AFP, Beta hCG, uE3 & Inhibin-A in the maternal blood. Ideally all pregnant women should be screened for prenatal disorders irrespective of maternal age
- Quadruple marker risk calculation is generated by using : Prisca 5.0.2.37 software based on Quadruple marker results, demographics like maternal age, weight, gestational age/LMP date, race and other risk factors like insulin dependent diabetes (IDD), smoking habits (if any) etc. Hence estimated risk calculations are dependent on accurate information provided by the patient. Inaccurate information can lead to false-positive or false-negative results
- Patient specific risks are generated in the form of analytical MoM (Multiples of Median) values and risk cutoff percentages and it represent the likelihood ratios for each parameter falling into an affected or unaffected risk for trisomy 21 & 18 based on the maternal age
- As the risk calculations are statistical approaches and have no diagnostic value a negative test does not necessarily rule out the absence of fetal defects and a positive test is not diagnostic but suggests need for further diagnosis. Hence a high risk report should be followed by tests like Amniocentesis for confirmation
- In case, if the provided LMP date/gestational age or other risk factors etc. needs any correction, the risk analysis will be recalculated according to the corrected parameters to avoid technical errors, if any

Generated On 14-Aug-2025 10:26:17

This is an electronically authenticated laboratory report.

Page 1 of 2



Sin No: 15215480

AMPATH
Central Reference Lab
Door No. 1-100/1/CCF
Serilingampally
Hyderabad



AMPATH
ACCURATE DIAGNOSTICS. AMERICAN STANDARDS.

LABORATORY REPORT

NAME	: MRS VANDANA KUMARI	REFERRED BY	: DR.PRATHIBHA ARCHANA	VISIT NO	: VAMP25289472
AGE	: 20Y 5M 12D		: DAS	COLLECTED ON	: 04-08-2025 12:00
GENDER	: Female	ADVANCE DIAGNOSTIC CENTER		RECEIVED ON	: 08-08-2025 14:03
OP / IP / DG #	:	LAB MR#	: AAMP01198360	APPROVED ON	: 09-08-2025 16:48
				REPORT STATUS	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

SOFTWARE GENERATED GRAPHICAL REPORT ATTACHED OVERLEAF.

Sanjeeta

Dr.Sanjeeta
Consultant- Biochemist

Disclaimer:

1. All results released pertain to the specimen as received by the lab for testing and under the assumption that the patient indicated or identified on the bill/test requisition form is the owner of the specimen.
2. Clinical details and consent forms, especially in Genetic testing, histopathology, as well as wherever applicable, are mandatory to be accompanied with the test requisition form. The non-availability of such information may lead to delay in reporting as well as misinterpretation of test results. The lab will not be responsible for any such delays or misinterpretations thereof.
3. Test results are dependent on the quality of the sample received by the lab. In case the samples are preprocessed elsewhere (e.g., paraffin blocks), results may be compromised.
4. Tests are performed as per the schedule given in the test listing and in any unforeseen circumstances, report delivery may be affected.
5. Test results may show inter-laboratory as well as intra-laboratory variations as per the acceptable norms.
6. Genetic reports as well as reports of other tests should be correlated with clinical details and other available test reports by a qualified medical practitioner. Genetic counselling is advised in genetic test reports by a qualified genetic counsellor, medical practitioner or both.
7. Samples will be discarded post processing after a specified period as per the laboratory's retention policy. Kindly get in touch with the lab for more information.
8. If accidental damage, loss, or destruction of the specimen is not attributable to any direct or negligent act or omission on the part of Ampath Labs or its employees, Ampath shall in no event be liable. Ampath lab's liability for a lack of services, or other mistakes and omissions, shall be restricted to the amount of the patient's payment for the pertinent laboratory services.

Generated On 14-Aug-2025 10:26:17

This is an electronically authenticated laboratory report.

Page 2 of 2

Sin No: 15215480



Amopath upholds rigorous standards for operational and clinical performance. Test results have been furnished in adherence with these standards and under terms and conditions found on the reverse. For details, please email Ampath at customersupport@ampath.com


American Institute Of Pathology and Laboratory Sciences Private Limited
H.NO. 1-111/4/B/103, Flat no. B-103
B - Block, Aparna Towers, Kothaguda Post, Kothaguda, Hyderabad - 500084

Result Down's syndrome screening

Name	VANDANA KUMARI	Sample ID	15215480	diabetes	no
	MRS	D.O.B.	25-02-2005	Fetuses	1
Patient ID	15215480	Age at delivery	20.8	Smoker	no
Day of serum taking	04-08-2025	Weight [kg]	66 kg	IVF	no
Date of report:	09-08-2025			Ethnic origin	Asian
Previous trisomy 21 pregnancies	no				

Corrected MoM's and calculated risks

AFP	50.2	ng/ml	0.60	Corr. MoM	Gestational age at sample date	21 + 2
uE3	1	ng/ml	0.54	Corr. MoM	determination method	BPD Hadlock
HCG	27396	mIU/ml	1.79	Corr. MoM	Physician	DR PRATHIBHA ARCHANA DAS
Inh-A	371.5	Pg/ml	2.07	Corr. MoM		



Tr.21 risk
at term
1:83

Age risk
at term
1:1522

Down's Syndrome Risk

The calculated risk for Trisomy 21 is above the cut off which represents an increased risk.
After the result of the Trisomy 21 test it is expected that among 83 women with the same data, there is one woman with a trisomy 21 pregnancy and 82 women with not affected pregnancies.
The calculated risk by PRISCA depends on the accuracy of the information provided by the referring physician.
Please note that risk calculations are statistical approaches and have no diagnostic value!

Neural tube defects risk

The corrected MoM AFP (0.60) is located in the low risk area for neural tube defects.

Risk for trisomy 18

The calculated risk for trisomy 18 is < 1:10000, which indicates a low risk.

below cut off

Below Cut Off, but above Age Risk

above cut off

Prisca 5.0.2.37